Placed on Senate Legislative Calendar under General Orders. Calendar No. 152.
This bill amends the Federal Food, Drug, and Cosmetic Act to revise, extend, and detail the user-fee program for over-the-counter (OTC) monograph drugs for fiscal years 2026–2030. It updates definitions to permit adoption of voluntary consensus testing standards, adjusts fee assessment periods and due dates, sets revenue components including specific dollar increases for fiscal years 2026–2028, and creates a one-time workload adjustment option for later years.
Progressives emphasize risks of industry-funded fees influencing FDA priorities; conservatives emphasize the fees and reporting as regulatory/financial burdens.
Relative to its intended legislative type, this bill is a well-specified statutory reauthorization and revision of the OTC monograph drug user-fee program.
This bill amends the Federal Food, Drug, and Cosmetic Act to revise, extend, and detail the user-fee program for over-the-counter (OTC) monograph drugs for fiscal years 2026–2030.
It updates definitions to permit adoption of voluntary consensus testing standards, adjusts fee assessment periods and due dates, sets revenue components including specific dollar increases for fiscal years 2026–2028, and creates a one-time workload adjustment option for later years.
The bill requires expanded annual FDA reporting on program goals, processing timelines, facility registration and fee payment, postmarket safety activities, and makes negotiation meeting minutes publicly available; it also directs GAO reports on OTC supply chains and on Rx-to-nonprescription switch activity.
On substance alone this is a targeted, technocratic reauthorization and modernization of an FDA user fee program — the type of measure that often becomes law because it funds regulatory activity and addresses process bottlenecks. Built-in transparency, sunsets, and GAO reporting reduce friction. Remaining risk stems from stakeholder disputes over specific technical provisions (sunscreen, testing standards, Rx-to-OTC switches), timing relative to appropriations, or procedural holds in the Senate.
Relative to its intended legislative type, this bill is a well-specified statutory reauthorization and revision of the OTC monograph drug user-fee program. It contains detailed fee-setting mechanics, explicit fiscal adjustments, implementation timelines, reporting and oversight requirements, and cross-references to existing law.
Progressives emphasize risks of industry-funded fees influencing FDA priorities; conservatives emphasize the fees and reporting as regulatory/financial burdens.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize risks of industry-funded fees influencing FDA priorities; conservatives emphasize the fees and reporting as regulatory/financial burdens.
A mainstream progressive would likely view the bill as mixed: it contains several positive public-interest elements (transparency in negotiation minutes, emphasis on non-animal testing, expanded safety and postmarket reporting, and attention to sunscreen safety), but it also extends and formalizes industry user fees that fund FDA activities.
They would welcome the requirements for public reporting and the move toward alternatives to animal testing, while remaining cautious that industry-funded fee programs can create incentives that shift agency priorities.
They would watch for whether the fees increase costs for smaller manufacturers or are passed to consumers, and for safeguards to preserve FDA independence.
A pragmatic moderate would view the bill as largely constructive: it provides stable, predictable funding for FDA work on OTC monograph drugs, increases transparency and reporting, and clarifies regulatory pathways (including Rx-to-nonprescription switches).
They would appreciate GAO studies of supply chains and the requirement for timely FDA guidance, while being attentive to fiscal and administrative details—timing of fee collection, overall cost to industry, and whether the fee mechanics create implementation problems.
They would balance the need for agency resources and predictable processes against the need for oversight and clear cost estimates.
A mainstream conservative would have mixed views: they would appreciate clearer, potentially market-friendly pathways for Rx-to-nonprescription switches (which can lower health costs and expand access) and the use of voluntary consensus standards, but they would be wary of expanded federal fee-collection mechanisms, additional regulatory reporting requirements, and any increase in bureaucratic activity.
They would scrutinize the fee increases, timing, and the potential for added regulatory burdens on manufacturers, while acknowledging benefits from clearer processes and improved supply-chain oversight.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On substance alone this is a targeted, technocratic reauthorization and modernization of an FDA user fee program — the type of measure that often becomes law because it funds regulatory activity and addresses process bottlenecks. Built-in transparency, sunsets, and GAO reporting reduce friction. Remaining risk stems from stakeholder disputes over specific technical provisions (sunscreen, testing standards, Rx-to-OTC switches), timing relative to appropriations, or procedural holds in the Senate.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize risks of industry-funded fees influencing FDA priorities; conservatives emphasize the fees and reporting as regulato…
On substance alone this is a targeted, technocratic reauthorization and modernization of an FDA user fee program — the type of measure that…
Relative to its intended legislative type, this bill is a well-specified statutory reauthorization and revision of the OTC monograph drug user-fee program. It contains detailed fee-setting mechanics, explicit fiscal adj…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.